Clinical Trial Update: A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu) [Phase 2]

View source ↗

Summary

Phase II study (XanADu) evaluating the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease completed with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Xanamem

Snippet

Sponsor: Actinogen Medical | Conditions: Dementia, Alzheimer Type | Phase 2 | Status: COMPLETED | Results posted: 2021-05-06